Sort

Search

01/02/2022 The endocrine role of brown adipose tissue: An update on actors and actions
Gavalda-Navarro, A, Villarroya, J, Cereijo, R, Giralt, M, Villarroya, F. The endocrine role of brown adipose tissue: An update on actors and actions. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS. 2022; 23(1)DOI:10.1007/s11154-021-09640-6. PMID:33712997. IF:8.200(Q1/1D).
01/02/2022 Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy
Domingo, P, Mateo, MG, Villarroya, J, Cereijo, R, Torres, F, Domingo, JC, Campderros, L, Gallego-Escuredo, JM, Gutierrez, MD, Mur, I, Corbacho, N, Vidal, F, Villarroya, F, Giralt, M. Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy. Journal of Clinical Medicine. 2022; 11(3)DOI:10.3390/jcm11030549. PMID:35160008. IF:3.900(Q2/4D).
01/02/2022 Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4(+) T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy
Yeregui, E, Masip, J, Vilades, C, Domingo, P, Pacheco, YM, Blanco, J, Mallolas, J, Alba, V, Vargas, M, Garcia-Pardo, G, Negredo, E, Olona, M, Vidal-Gonzalez, J, Peraire, M, Marti, A, Reverte, L, Gomez-Bertomeu, F, Leal, M, Vidal, F, Peraire, J, Rull, A. Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4(+) T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(4)DOI:10.3390/ijms23042202. PMID:35216318. IF:5.600(Q1/3D).
01/02/2022 A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
Sooy, RA, Han, JY, Dafni, U, Cho, BC, Yeo, CM, Nadal, E, Carcereny, E, de Castro, J, Sala, MA, Bernabee, R, Coate, L, Pulla, MP, Campelo, RG, Cuffe, S, Hashemi, SMS, Fruh, M, Massuti, B, Garcia-Sanchez, J, Domine, M, Majem, M, Sanchez-Torres, JM, Britschgi, C, Pless, M, Dimopoulou, G, Roschitzki-Voser, H, Ruepp, B, Rosell, R, Stahel, RA, Peters, S. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. ANNALS OF ONCOLOGY. 2022; 33(2)DOI:10.1016/j.annonc.2021.11.010. PMID:34839016. IF:50.500(Q1/1D).